Jan-Anders Karlsson says the recent strengthening of its management team has given Verona Pharma PLC (LON:VRP) the experience to take its respiratory disease treatment Ensifentrine to market.
LONDON, Feb. 21, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its audited financial results for the full year ended December 31, 2019 on Thursday,
Paper demonstrates ensifentrine’s potential in improving lung function and quality of life symptoms
LONDON, Feb. 07, 2020 (GLOBE NEWSWIRE) -- TR-1: Standard form for notification of major holdings
Get the latest stock price information, including historical values and our investment calculator.